Biliary cancers, chemotherapy, and cetuximab

David Malka; Valérie Boige; Michel Ducreux

doi:10.1016/s1470-2045(10)70267-9

Biliary cancers, chemotherapy, and cetuximab

David Malka
, Valérie Boige
, Michel Ducreux

Institut Gustave Roussy

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	1110-1112
Number of pages	3
Journal	The Lancet Oncology
Volume	11
Issue number	12
DOIs	https://doi.org/10.1016/s1470-2045(10)70267-9
State	Published - Dec 2010
Externally published	Yes

Bibliographical note

Funding Information:
The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.

Funding

The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.

Funders
Merck Serono
Amgen
Pfizer
GlaxoSmithKline
Roche
Fresenius Biotech

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s1470-2045(10)70267-9

Cite this

@article{02f636b6b9f940d18d40ab19e6da4f99,

title = "Biliary cancers, chemotherapy, and cetuximab",

author = "David Malka and Val{\'e}rie Boige and Michel Ducreux",

note = "Funding Information: The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.",

year = "2010",

month = dec,

doi = "10.1016/s1470-2045(10)70267-9",

language = "אנגלית",

volume = "11",

pages = "1110--1112",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - Biliary cancers, chemotherapy, and cetuximab

AU - Malka, David

AU - Boige, Valérie

AU - Ducreux, Michel

N1 - Funding Information: The authors' institution has received grants from Merck Serono, Sanofi-Aventis France, Roche, and Amgen; and consultancy fees from Roche. DM has received consulting fees or honorarium from Merck Serono; has been a consultant for, and has received payment for development of educational presentations, and support for travel and accommodation to meetings from Roche; and has received payment for lectures from Merck Serono, Sanofi-Aventis. France, Amgen, and Roche. VB has received consulting fees or honorarium from Merck Serono and Amgen; has received support for travel to meetings from Merck Serono, Amgen, Bayer Schering Pharma, and Roche; has been a board member for, and has received payment for lectures, and development of educational presentations from Bayer Schering Pharma; and has been a consultant for Pfizer. MD has received consulting fees or honorarium, and support for travel to meetings from Merck Serono; has been a board member for Roche, Pfizer, Amgen, and Fresenius Biotech; has received grants from Roche; has received payment for lectures from Roche, Amgen, and Pfizer; and his wife is employed by the French affiliate of GlaxoSmithKline.

PY - 2010/12

Y1 - 2010/12

UR - https://www.scopus.com/pages/publications/78649600834

U2 - 10.1016/s1470-2045(10)70267-9

DO - 10.1016/s1470-2045(10)70267-9

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 21126684

AN - SCOPUS:78649600834

SN - 1470-2045

VL - 11

SP - 1110

EP - 1112

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 12

ER -

Biliary cancers, chemotherapy, and cetuximab

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Cite this